InventisBio Co., Limited (SHA:688382)
China
· Delayed Price · Currency is CNY 21.39
+1.42 (7.11%)
Mar 6, 2026, 4:00 PM EST
InventisBio Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 37.33 | 168.79 | 185.53 | - | - | Upgrade
|
| Revenue Growth (YoY) | -77.89% | -9.02% | - | - | - | Upgrade
|
| Cost of Revenue | - | 3.92 | - | - | - | Upgrade
|
| Gross Profit | 37.33 | 164.87 | 185.53 | - | - | Upgrade
|
| Selling, General & Admin | - | 52.5 | 60.85 | 57.96 | 47.71 | Upgrade
|
| Research & Development | - | 384.35 | 442.91 | 461.49 | 315.04 | Upgrade
|
| Other Operating Expenses | 353.92 | 0.09 | 0.12 | -0 | 0.05 | Upgrade
|
| Operating Expenses | 353.92 | 445.82 | 513.18 | 519.44 | 362.8 | Upgrade
|
| Operating Income | -316.6 | -280.95 | -327.65 | -519.44 | -362.8 | Upgrade
|
| Interest Expense | - | -0.66 | -0.83 | -1.03 | -1.19 | Upgrade
|
| Interest & Investment Income | - | 30.02 | 40.45 | 17.38 | 12.76 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.56 | 1.18 | 19.99 | -11.33 | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0.11 | -0.27 | -0.2 | -0.21 | Upgrade
|
| EBT Excluding Unusual Items | -316.6 | -250.14 | -287.12 | -483.31 | -362.76 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 1.3 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.08 | - | - | 0 | Upgrade
|
| Other Unusual Items | - | 8.57 | 3.15 | -0.18 | 4.85 | Upgrade
|
| Pretax Income | -316.6 | -240.2 | -283.98 | -483.49 | -357.91 | Upgrade
|
| Income Tax Expense | 0.24 | - | - | - | - | Upgrade
|
| Net Income | -316.84 | -240.2 | -283.98 | -483.49 | -357.91 | Upgrade
|
| Net Income to Common | -316.84 | -240.2 | -283.98 | -483.49 | -357.91 | Upgrade
|
| Shares Outstanding (Basic) | 576 | 576 | 575 | 509 | 459 | Upgrade
|
| Shares Outstanding (Diluted) | 576 | 576 | 575 | 509 | 459 | Upgrade
|
| Shares Change (YoY) | -0.07% | 0.26% | 12.97% | 10.91% | -0.25% | Upgrade
|
| EPS (Basic) | -0.55 | -0.42 | -0.49 | -0.95 | -0.78 | Upgrade
|
| EPS (Diluted) | -0.55 | -0.42 | -0.49 | -0.95 | -0.78 | Upgrade
|
| Free Cash Flow | - | -249.53 | -314.04 | -484.59 | -278.59 | Upgrade
|
| Free Cash Flow Per Share | - | -0.43 | -0.55 | -0.95 | -0.61 | Upgrade
|
| Gross Margin | 100.00% | 97.67% | 100.00% | - | - | Upgrade
|
| Operating Margin | -848.21% | -166.45% | -176.61% | - | - | Upgrade
|
| Profit Margin | -848.86% | -142.31% | -153.06% | - | - | Upgrade
|
| Free Cash Flow Margin | - | -147.84% | -169.27% | - | - | Upgrade
|
| EBITDA | -311.13 | -275.49 | -322.31 | -514.77 | -360.15 | Upgrade
|
| EBITDA Margin | - | -163.21% | -173.73% | - | - | Upgrade
|
| D&A For EBITDA | 5.47 | 5.47 | 5.34 | 4.68 | 2.64 | Upgrade
|
| EBIT | -316.6 | -280.95 | -327.65 | -519.44 | -362.8 | Upgrade
|
| EBIT Margin | - | -166.45% | -176.61% | - | - | Upgrade
|
| Revenue as Reported | - | 168.79 | 185.53 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.